MiNK Therapeutics (NASDAQ:INKT) Stock: Insider Jennifer Buell Sells 6,938 Shares

MiNK Therapeutics, Inc. (NASDAQ:INKT) CEO Jennifer Buell sold 6,938 shares of the business’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $10.56, for a total transaction of $73,265.28. Following the completion of the sale, the chief executive officer directly owned 74,195 shares in the company, valued at $783,499.20. This trade represents a 8.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

MiNK Therapeutics Stock Performance

Shares of INKT stock opened at $9.94 on Friday. MiNK Therapeutics, Inc. has a 52-week low of $8.48 and a 52-week high of $16.93. The stock has a market cap of $50.72 million, a price-to-earnings ratio of -4.14 and a beta of 0.47. The firm has a fifty day moving average of $11.57 and a 200-day moving average of $11.47.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). On average, sell-side analysts predict that MiNK Therapeutics, Inc. will post -1.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Friday, October 2nd. Zacks Research downgraded MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, MiNK Therapeutics has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. The company’s research centers on invariant natural killer T (iNKT) cells, an immune cell type that can recognize and attack tumor cells while helping activate broader immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed for use as an off-the-shelf treatment. The candidate has been evaluated in clinical studies involving patients with advanced cancers, including solid tumors and hematologic malignancies, both as a standalone therapy and in combination with other cancer treatments.

The company is also advancing its broader iNKT cell therapy platform and additional product candidates intended to address challenges such as tumor immunosuppression and limited immune-cell activity within solid tumors.